Gene fusions are vital biomarkers for tumor diagnosis and drug development, with precise detection becoming increasingly ...

Scientists at Flinders University in Australia have made a discovery that could change how we understand cancer’s origins.

In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) ...

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

China's HL-3 tokamak, a leading "artificial sun" device, now features a digital twin system for real-time monitoring.

The U.S. Food and Drug Administration on Tuesday extended the review of Merus NV's gene-targeting cancer therapy to allow sufficient time to review some recent information submitted by the company.

The FDA is set to decide on four promising therapies in the next two weeks, including a CAR T for acute lymphoblastic ...

The 4-year overall survival rate was 86%. Waguespack closed with a cautionary note to colleagues: “While circulating tumor DNA next-generation sequencing (NGS) analysis can be used to test for NTRK ...

NRG1 fusions are gene fusions regarded as oncogenic drivers and can be found in various tumor types. The Biologics License Application for Zeno was accepted by the U.S. regulatory agency on May 6, ...

a distinguished professor in the Shu Chien-Gene Lay Department of Bioengineering at the University of California San Diego. Digestion requires powerful enzymes that are synthesized in the pancreas.